Shares of health-care companies rose, but not by as much as the broad market, as traders rotated into sectors less sensitive to regulatory risk. Shares of Amgen declined after the biotech giant said an osteoperosis treatment it co-developed had an unexpectedly high incidence of side effects in a clinical trial.
Continue Reading Below
-Rob Curran, firstname.lastname@example.org
(END) Dow Jones Newswires
May 22, 2017 16:27 ET (20:27 GMT)